Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours
This study is testing an oral medication called zongertinib to see if it helps adults with advanced solid tumor cancers that have specific HER2 genetic changes. It is designed for patients who have already tried other treatments that were not successful.
You may be able to join if you are 18 or older, have advanced cancer with confirmed HER2 gene changes, and have a saved tumor sample available for testing. Certain conditions apply, such as having no remaining standard treatment options and not having specific types of lung, breast, or stomach cancers included in other studies.
Participants will take zongertinib pills daily by mouth and visit the study clinic regularly. During these visits, doctors will monitor your overall health, check for side effects, and use scans to see how your tumor is responding to the treatment.
The study is currently recruiting participants at multiple locations, including sites in Alaska, Arizona, and California. You can continue taking the study medication as long as you are benefiting from it and tolerating it well.
- 1Testing an oral targeted therapy called zongertinib for advanced cancers with HER2 changes.
- 2Designed for adults who have tried previous treatments that stopped working.
- 3Involves taking daily pills and regular check-ups to monitor tumor size and side effects.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.